Andere Sprachen SpringWorks Therapeutics, Inc.

Aktien

A2PRLN

US85205L1070

SWTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:13:39 23.05.2024			% 5 Tage	% 1. Jan.
43,2 ^USD	-2,43 %		-3,64 %	+18,19 %

15.05.	Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
02.05.	SPRINGWORKS THERAPEUTICS, INC. : Wedbush bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference	08.05.
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	02.05.
SpringWorks Therapeutics: Q1 Earnings Snapshot	02.05.
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	02.05.
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	02.05.
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	18.04.
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	04.03.
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04.03.
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04.03.
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29.02.
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29.02.
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	27.02.
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
SpringWorks Therapeutics: Q4 Earnings Snapshot	27.02.
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	27.02.
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	27.02.
SpringWorks Therapeutics to Present at Upcoming Investor Conferences	22.02.
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SpringWorks Therapeutics, Inc.

Aktien

A2PRLN

US85205L1070

SWTX

Andere Sprachen

Filter